|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 February 2002, Vol. 99, No. 4, pp. 1103-1108
PLENARY PAPER
Arginine supplementation of sickle transgenic mice reduces red
cell density and Gardos channel activity
José R. Romero,
Sandra M. Suzuka,
Ronald L. Nagel, and
Mary E. Fabry
From the Endocrine-Hypertension Division, Brigham and
Women's Hospital, Harvard Medical School, Boston, MA; and Division of
Hematology, Albert Einstein College of Medicine, Montefiore Medical
Center, Bronx, NY.
Nitric oxide (NO), essential for maintaining vascular tone,
is produced from arginine by nitric oxide synthase. Plasma arginine levels are low in sickle cell anemia, and it is reported here that low plasma arginine is also found in our sickle transgenic mouse
model that expresses human  , human  S, and human
S-Antilles and is homozygous for the mouse
major deletion (S+S-Antilles). S+S-Antilles mice were
supplemented with a 4-fold increase in arginine that was maintained for
several months. Mean corpuscular hemoglobin concentration (MCHC)
decreased and the percent high-density red cells was reduced. Deoxy
K+ efflux is characteristic of red cells in sickle cell
disease and contributes to the disease process by increasing the MCHC and rendering the cells more susceptible to polymer formation. This
flux versus the room air flux was reduced in S+S-Antilles red cells
from an average value of 1.6 ± 0.3 mmol per liter of red cells × minute (FU) in nonsupplemented mice to 0.9 ± 0.3 FU (n = 4, P < .02, paired t test) in
supplemented mice. In room air, Vmax of the
Ca++-activated K+ channel (Gardos) was reduced
from 4.1 ± 0.6 FU (off diet) to 2.6 ± 0.4 FU (n = 7 and 8, P < .04, t test) in arginine-supplemented mice versus clotrimazole. In conclusion, the major mechanism by which
arginine supplementation reduces red cell density (MCHC) in
S+S-Antilles mice is by inhibiting the Ca++-activated
K+ channel.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G. J. Kato and M. T. Gladwin
Evolution of Novel Small-Molecule Therapeutics Targeting Sickle Cell Vasculopathy
JAMA,
December 10, 2008;
300(22):
2638 - 2646.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Krajewski, L. L. Hsu, and M. T. Gladwin
The proverbial chicken or the egg? Dissection of the role of cell-free hemoglobin versus reactive oxygen species in sickle cell pathophysiology
Am J Physiol Heart Circ Physiol,
July 1, 2008;
295(1):
H4 - H7.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. K. Kaul, X. Zhang, T. Dasgupta, and M. E. Fabry
Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress
Am J Physiol Heart Circ Physiol,
July 1, 2008;
295(1):
H39 - H47.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. R. Morris
Mechanisms of Vasculopathy in Sickle Cell Disease and Thalassemia
Hematology,
January 1, 2008;
2008(1):
177 - 185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Kato
Novel Small Molecule Therapeutics for Sickle Cell Disease: Nitric Oxide, Carbon Monoxide, Nitrite, and Apolipoprotein A-I
Hematology,
January 1, 2008;
2008(1):
186 - 192.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Rivera
Reduced sickle erythrocyte dehydration in vivo by endothelin-1 receptor antagonists
Am J Physiol Cell Physiol,
September 1, 2007;
293(3):
C960 - C966.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. T. Gladwin and G. J. Kato
Cardiopulmonary Complications of Sickle Cell Disease: Role of Nitric Oxide and Hemolytic Anemia
Hematology,
January 1, 2005;
2005(1):
51 - 57.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Fabry, Z. Etzion, R. M. Bookchin, S. M. Suzuka, and R. L. Nagel
Arginine Supplementation of Sickle Transgenic Mice Leads to a Rapid Decrease in MCHC and Percent Dense Cells and a Slow Increase When Supplementation Is Discontinued.
Blood (ASH Annual Meeting Abstracts),
November 16, 2004;
104(11):
3579 - 3579.
[Abstract]
|
|
|
|
|
|
|
J. H. Schwartz, C. A. White, and B. A. Freeman
Do we kNOw how HSP90 and eNOS mediate lung injury in sickle cell disease?
Am J Physiol Lung Cell Mol Physiol,
April 1, 2004;
286(4):
L701 - L704.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Romero, S. M. Suzuka, R. L. Nagel, and M. E. Fabry
Expression of HbC and HbS, but not HbA, results in activation of K-Cl cotransport activity in transgenic mouse red cells
Blood,
March 15, 2004;
103(6):
2384 - 2390.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. de Franceschi, A. Baron, A. Scarpa, C. Adrie, A. Janin, S. Barbi, J. Kister, P. Rouyer-Fessard, R. Corrocher, P. Leboulch, et al.
Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation
Blood,
August 1, 2003;
102(3):
1087 - 1096.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. R. Morris, S. M. Morris Jr., W. Hagar, J. van Warmerdam, S. Claster, D. Kepka-Lenhart, L. Machado, F. A. Kuypers, and E. P. Vichinsky
Arginine Therapy: A New Treatment for Pulmonary Hypertension in Sickle Cell Disease?
Am. J. Respir. Crit. Care Med.,
July 1, 2003;
168(1):
63 - 69.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
